Mary Jeanne Kallman - Concepedia

Author

Mary Jeanne Kallman

Also Known As

M J KALLMAN, M J Kallman, M Kallman, M. J. KALLMAN, M. J. Kallman, M. Kallman, M.J. Kallman, Mary J Kallman, Mary J. Kallman, Mary Jeanne Kallman

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)University of Mississippi Virginia Commonwealth University Virginia Commonwealth University Medical Center

About

Mary Jeanne Kallman is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	1K
2	Health Sciences	7	7	137
3	Social Sciences	5	5	245
4	Natural Sciences	2	2	492
5	Engineering	1	1	11

Mary Jeanne Kallman

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Design, Synthesis, and Pharmacological Characterization of (+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740): A Potent, Selective, and Orally Active Group 2 Metabotropic Glutamate Receptor Agonist Possessing Anticonvulsant and Anxiolytic Properties James A. Monn, Matthew J. Valli, Steven M. Massey, Journal of Medicinal Chemistry Pharmacological CharacterizationActive Group 2Psychotropic MedicationPharmacotherapyChemical Biology	1997	392
Anxiolytic and Side-Effect Profile of LY354740: A Potent, Highly Selective, Orally Active Agonist for Group II Metabotropic Glutamate Receptors David R. Helton, J P Tizzano, James A. Monn, Journal of Pharmacology and Experimental Therapeutics	1998	282
Benchmarking Safety Pharmacology regulatory packages and best practice Silvana Lindgren, Alan Bass, Richard J. Briscoe, Journal of Pharmacological and Toxicological Methods Drug SafetyMedicinePharmacovigilanceRegulatory Safety SciencePharmacology	2008	107
LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats David R. Helton, Joseph P. Tizzano, James A. Monn, Neuropharmacology Molecular PharmacologyNicotine WithdrawalBehavioral NeuroscienceAddictionNeurophysiology	1997	103
2-Substituted (2<i>SR</i>)-2-Amino-2-((1<i>SR</i>,2<i>SR</i>)-2-carboxycycloprop-1-yl)glycines as Potent and Selective Antagonists of Group II Metabotropic Glutamate Receptors. 2. Effects of Aromatic Substitution, Pharmacological Characterization, and Bioavailability Paul L. Ornstein, Thomas J. Bleisch, M. Brian Arnold, Journal of Medicinal Chemistry Pharmacological CharacterizationSynaptic TransmissionPharmacotherapyChemical BiologyExperimental Pharmacology	1998	100
LY303870, a Centrally Active Neurokinin-1 Antagonist with a Long Duration of Action Satish Iyengar, Philip A. Hipskind, Donald R. Gehlert, Journal of Pharmacology and Experimental Therapeutics	1997	58
The Novel 5-Hydroxytryptamine1A Antagonist LY426965: Effects on Nicotine Withdrawal and Interactions with Fluoxetine Kurt Rasmussen, David O. Calligaro, Janet F. Czachura, Journal of Pharmacology and Experimental Therapeutics	2000	58
Hallucinogenic agents as discriminative stimuli: A correlation with serotonin receptor affinities Richard A. Glennon, Richard Young, John A. Rosecrans, Psychopharmacology Serotonin Receptor AffinitiesNeuropsychologyPsychoactive DrugPsychiatryMedicine	1980	46
Serotonin-1A antagonists attenuate the effects of nicotine withdrawal on the auditory startle response Kurt Rasmussen, Mary Jeanne Kallman, David R. Helton Synapse	1997	45
Evaluation of the Reinforcing Effects of Monoamine Reuptake Inhibitors Under a Concurrent Schedule of Food and I.V. Drug Delivery in Rhesus Monkeys Maciej Gąsior, Jack Bergman, Mary Jeanne Kallman, Neuropsychopharmacology Pharmacological StudyBehavioral NeuroscienceAddictionMedicineBehavioral Pharmacology	2004	40

Page 1